Peritoneal Dialysis Market by Product Type (Accessories, PD Machines, Peritoneal Solution), Therapeutic Area (Acute Kidney Injury, Chronic Kidney Disease, Congestive Heart Failure), Application, End User - Global Forecast 2025-2032
Description
The Peritoneal Dialysis Market was valued at USD 9.60 billion in 2024 and is projected to grow to USD 9.98 billion in 2025, with a CAGR of 5.91%, reaching USD 15.20 billion by 2032.
Concise overview of the clinical, technological, regulatory, and care delivery dynamics shaping peritoneal dialysis strategy and stakeholder priorities
Peritoneal dialysis continues to be a pivotal therapy modality for patients with renal insufficiency, offering an alternative to hemodialysis that emphasizes patient autonomy, flexibility, and home-based care. Stakeholders across healthcare systems, device manufacturers, solution suppliers, and care providers are navigating an environment shaped by clinical innovation, shifting care models, and heightened attention to cost-effectiveness and patient-centered outcomes. In this context, a concise executive summary can illuminate the forces reshaping adoption, technology development, and care delivery pathways.
This introduction situates the reader within the current clinical and commercial landscape by highlighting the interplay between technological advances-such as automation and biocompatible solutions-and evolving care settings, notably the expansion of home healthcare programs. It underscores the importance of integrating clinical evidence, operational feasibility, and patient experience into strategic planning. Moreover, it emphasizes that regulatory frameworks, reimbursement policies, and supply chain considerations are equally determinative of market trajectories, requiring cross-functional coordination among clinical leaders, procurement teams, and commercial strategists. By framing these drivers, the introduction prepares decision-makers to interpret subsequent sections that detail shifts, tariff impacts, segmentation insights, regional dynamics, competitor positioning, and recommended actions.
How innovations in automation, solution biocompatibility, care delivery models, and remote monitoring are reshaping peritoneal dialysis practice and commercial strategy
The landscape of peritoneal dialysis is undergoing transformative shifts driven by converging clinical, technological, and delivery-model trends. Advancements in cycler automation and continuous ambulatory techniques are enabling more individualized therapy regimens, while improvements in solution biocompatibility are reducing treatment-related complications and extending therapy longevity for patients managing chronic kidney disease. Concurrently, the emergence of data-enabled devices and remote monitoring capabilities is facilitating tighter clinical oversight and better adherence, which in turn supports broader uptake in home healthcare settings.
Transitioning care pathways are altering market incentives and operational workflows. Dialysis centers are reconfiguring service mixes to include training and support for home-based therapy, and hospitals are integrating peritoneal dialysis protocols for acute kidney injury management. At the same time, suppliers are innovating across accessory design, catheter kits, and transfer systems to simplify procedures and lower the learning curve for patients and caregivers. These shifts are further intertwined with payer and policy trends that prioritize value-based care, prompting manufacturers and providers to demonstrate real-world outcomes and total cost-of-care benefits. Together, these dynamics are reshaping how products are developed, how services are delivered, and how patients experience long-term renal replacement therapy.
Operational and strategic effects of 2025 U.S. tariff measures on supply chains, procurement behavior, and commercial negotiations across the peritoneal dialysis sector
The introduction of tariffs by the United States in 2025 has introduced a complex set of pressures across supply chains, procurement strategies, and pricing negotiations for peritoneal dialysis stakeholders operating in and exporting to the U.S. market. Manufacturers that source components or finished products internationally have had to reassess sourcing decisions, renegotiate supplier contracts, and examine nearshoring or dual-sourcing options to maintain continuity of supply. These operational responses have implications for lead times, inventory policies, and the margin structures of distributors and providers that procure equipment, solutions, and accessories.
Healthcare providers and purchasing organizations have reacted by intensifying supplier qualification processes and by seeking local production partnerships to mitigate exposure to tariff volatility. Regulatory compliance and customs procedures have taken on greater significance, prompting some firms to invest in logistics and trade expertise to navigate classification and duty mitigation strategies. In parallel, innovation pipelines have been reviewed for cost-efficiency in component selection and manufacturing processes, with research and development teams prioritizing designs that permit modular assembly and regional adaptation. As a result, commercial negotiations increasingly emphasize total landed cost, reliability of supply, and contractual protections against future trade disruptions, thereby refocusing strategic planning across the industry.
Segment-driven priorities that clarify product development, clinical focus, and service model adaptations across distinct product, therapeutic, application, and end-user categories
Insights derived from a structured segmentation framework reveal nuanced demand drivers and innovation opportunities across product type, therapeutic area, application, and end user. When viewed by product type, the market encompasses accessories, PD machines, and peritoneal solutions, each provoking distinct development priorities: accessories such as bags for PD solutions, drainage bags, peritoneal dialysis catheter kits, and transfer sets require continuous improvements in aseptic design and user ergonomics to reduce infection risk and simplify home use; PD machines, including automated peritoneal dialysis cyclers and continuous ambulatory peritoneal dialysis devices, generate focus on portability, battery life, connectivity, and user interfaces that enable remote monitoring and clinical oversight; peritoneal solutions, spanning biocompatible solutions, glucose-based solutions, and low-glucose solutions, drive clinical research around membrane preservation, metabolic outcomes, and tolerability.
Shifting to therapeutic area segmentation, acute kidney injury, chronic kidney disease, and congestive heart failure present differing clinical pathways and adoption imperatives, with acute settings prioritizing rapid availability and interchangeable protocols, while chronic care emphasizes long-term tolerability and patient training. Application segmentation underscores the variable etiologies underpinning therapy choice: diabetic nephropathy, glomerulonephritis, lupus nephritis, and polycystic kidney disease each carry distinct comorbidity profiles and treatment adherence challenges that influence product selection and support services. Finally, end-user segmentation across dialysis centers, home healthcare, and hospitals highlights the need for tailored distribution, training, and service models: dialysis centers require volumetric supply and integration with clinical workflows; home healthcare providers need simplified devices, telehealth integration, and caregiver education; hospitals demand rapid case integration and cross-disciplinary protocols. These layered segmentation insights inform prioritization of R&D, commercialization strategies, and service delivery models.
How regional healthcare infrastructures, reimbursement systems, and logistical realities in the Americas, Europe Middle East & Africa, and Asia-Pacific determine commercialization and access approaches
Regional dynamics in peritoneal dialysis reflect differences in healthcare infrastructure, reimbursement paradigms, clinical practice patterns, and supply chain resilience across major geographies. In the Americas, stakeholders contend with a complex payer environment and a mix of large acute care networks and homecare service providers, prompting suppliers to emphasize reimbursement support, training programs, and partnerships that facilitate home therapy initiation. Regulatory pathways and state-level policy variations also influence device registration timelines and pricing strategies, requiring localized market access tactics.
Across Europe, the Middle East & Africa, diverse healthcare systems, public procurement frameworks, and variable infrastructure levels create distinct entry strategies and partnership models. Suppliers often pursue collaborations with regional distributors and clinical champions to demonstrate safety and effectiveness, while also adapting packaging, storage, and service offerings to local logistical realities. Meanwhile, Asia-Pacific presents heterogeneous demand drivers, with some advanced markets accelerating adoption of automation and telehealth-enabled solutions, and others prioritizing cost-efficient disposable accessories and centralized training to scale home-based therapy. In all regions, innovation adoption is moderated by clinician acceptance, patient education, and supply continuity, underscoring the importance of region-specific market intelligence when designing commercial and clinical engagement plans.
Competitive differentiation through integrated device-solution ecosystems, biocompatible chemistry advances, and service-rich commercialization models that drive provider and payer engagement
Competitive positioning within the peritoneal dialysis space is shaped by companies that combine product innovation with service delivery, regulatory expertise, and distribution reach. Leading manufacturers are investing in integrated solutions that couple user-friendly cyclers and accessories with remote monitoring capabilities and training platforms to reduce clinical burden and improve patient retention. Others are differentiating through advances in peritoneal solution chemistry, focusing on formulations that enhance membrane biocompatibility and patient metabolic profiles, thereby addressing long-term therapy durability.
Strategic collaborations and targeted acquisitions are common tactics to broaden portfolios and accelerate entry into adjacent care settings. Firms with robust manufacturing footprints are leveraging scale and quality systems to secure supply contracts with large hospital networks and homecare providers, while emerging entrants often focus on niche innovations-such as simplified transfer sets or infection-resistant catheter materials-to gain clinical traction. Across the competitive landscape, companies that combine clinical evidence generation, post-market support services, and flexible commercial models tend to achieve stronger engagement with payers and providers. Consequently, sustained investment in clinical studies, training infrastructure, and localized regulatory pathways remains central to competitive differentiation.
Practical strategic actions for manufacturers, providers, and payers to align clinical validation, supply chain resilience, service expansion, and digital engagement for scalable growth
Industry leaders should pursue a coordinated set of actions to capitalize on clinical trends and mitigate operational risks while enhancing patient-centric care. First, aligning product development priorities with clinical evidence goals will accelerate adoption; this means designing studies that address membrane preservation, infection reduction, and real-world adherence, and then translating findings into provider-facing value propositions. Second, establishing resilient supply chains is essential: diversifying sourcing, investing in local manufacturing where feasible, and implementing inventory strategies to withstand trade volatility will reduce disruption risk. Third, expanding service offerings-such as remote monitoring, structured training programs, and bundled support for home therapy initiation-will enhance patient outcomes and differentiate commercial propositions.
In addition, companies should foster payer dialogues to articulate total care benefits and to explore reimbursement models that support home-based therapies. Partnerships with dialysis centers, hospitals, and home healthcare organizations can facilitate pilot programs that demonstrate operational feasibility and capture early-adopter feedback. Finally, leveraging digital tools for patient engagement and adherence tracking can generate actionable data for continuous product improvement and for demonstrating value to clinical and financial stakeholders. Together, these actions create synergistic benefits across clinical performance, commercial traction, and supply chain resilience.
A rigorous mixed-methods approach combining clinician and industry interviews, regulatory and clinical literature review, and supply chain analysis to derive balanced sector insights
The research methodology underpinning this analysis integrates multidisciplinary inputs to ensure a robust and balanced view of the peritoneal dialysis landscape. Primary sources included structured interviews with clinical specialists, procurement leaders, and senior executives across device and solution companies, supplemented by consultations with homecare providers and hospital administrators to capture operational perspectives. Secondary research encompassed peer-reviewed clinical literature, regulatory filings, device registries, and policy documents to validate clinical trends and to interpret regulatory and reimbursement contexts.
Qualitative synthesis was applied to reconcile divergent viewpoints and to surface consensus themes, while thematic analysis identified recurring challenges and opportunities across product types, therapeutic areas, and care settings. Supply chain and tariff impact assessments were developed through trade data review and industry stakeholder interviews to capture operational responses and mitigation strategies. Care was taken to cross-validate insights across multiple information streams and to highlight areas where evidence is evolving, ensuring that conclusions reflect current practice and plausible near-term developments rather than speculative projections.
Integrated takeaways that align clinical innovation, adaptive commercialization, and supply chain resilience to advance patient outcomes and organizational competitiveness
In summary, peritoneal dialysis sits at the intersection of clinical innovation, evolving care delivery models, and operational complexity. Advances in automation, biocompatible solutions, and digital monitoring are expanding the clinical viability and appeal of home-based therapy, while tariff-driven supply chain recalibrations and regional healthcare differences require nimble commercial and manufacturing strategies. Segmentation insights point to differentiated needs across products, therapeutic areas, applications, and end users, calling for targeted R&D, tailored training, and adaptive distribution models.
Decision-makers should therefore prioritize investments that strengthen clinical evidence, improve patient support infrastructure, and secure supply chain resilience. By aligning product design with real-world care pathways and by fostering collaborations across providers and payers, organizations can better position themselves to deliver clinical value and to scale services responsibly. As the sector continues to evolve, ongoing monitoring of regulatory shifts, reimbursement policies, and technological breakthroughs will be essential for sustaining competitive advantage and for improving patient outcomes over the long term.
Please Note: PDF & Excel + Online Access - 1 Year
Concise overview of the clinical, technological, regulatory, and care delivery dynamics shaping peritoneal dialysis strategy and stakeholder priorities
Peritoneal dialysis continues to be a pivotal therapy modality for patients with renal insufficiency, offering an alternative to hemodialysis that emphasizes patient autonomy, flexibility, and home-based care. Stakeholders across healthcare systems, device manufacturers, solution suppliers, and care providers are navigating an environment shaped by clinical innovation, shifting care models, and heightened attention to cost-effectiveness and patient-centered outcomes. In this context, a concise executive summary can illuminate the forces reshaping adoption, technology development, and care delivery pathways.
This introduction situates the reader within the current clinical and commercial landscape by highlighting the interplay between technological advances-such as automation and biocompatible solutions-and evolving care settings, notably the expansion of home healthcare programs. It underscores the importance of integrating clinical evidence, operational feasibility, and patient experience into strategic planning. Moreover, it emphasizes that regulatory frameworks, reimbursement policies, and supply chain considerations are equally determinative of market trajectories, requiring cross-functional coordination among clinical leaders, procurement teams, and commercial strategists. By framing these drivers, the introduction prepares decision-makers to interpret subsequent sections that detail shifts, tariff impacts, segmentation insights, regional dynamics, competitor positioning, and recommended actions.
How innovations in automation, solution biocompatibility, care delivery models, and remote monitoring are reshaping peritoneal dialysis practice and commercial strategy
The landscape of peritoneal dialysis is undergoing transformative shifts driven by converging clinical, technological, and delivery-model trends. Advancements in cycler automation and continuous ambulatory techniques are enabling more individualized therapy regimens, while improvements in solution biocompatibility are reducing treatment-related complications and extending therapy longevity for patients managing chronic kidney disease. Concurrently, the emergence of data-enabled devices and remote monitoring capabilities is facilitating tighter clinical oversight and better adherence, which in turn supports broader uptake in home healthcare settings.
Transitioning care pathways are altering market incentives and operational workflows. Dialysis centers are reconfiguring service mixes to include training and support for home-based therapy, and hospitals are integrating peritoneal dialysis protocols for acute kidney injury management. At the same time, suppliers are innovating across accessory design, catheter kits, and transfer systems to simplify procedures and lower the learning curve for patients and caregivers. These shifts are further intertwined with payer and policy trends that prioritize value-based care, prompting manufacturers and providers to demonstrate real-world outcomes and total cost-of-care benefits. Together, these dynamics are reshaping how products are developed, how services are delivered, and how patients experience long-term renal replacement therapy.
Operational and strategic effects of 2025 U.S. tariff measures on supply chains, procurement behavior, and commercial negotiations across the peritoneal dialysis sector
The introduction of tariffs by the United States in 2025 has introduced a complex set of pressures across supply chains, procurement strategies, and pricing negotiations for peritoneal dialysis stakeholders operating in and exporting to the U.S. market. Manufacturers that source components or finished products internationally have had to reassess sourcing decisions, renegotiate supplier contracts, and examine nearshoring or dual-sourcing options to maintain continuity of supply. These operational responses have implications for lead times, inventory policies, and the margin structures of distributors and providers that procure equipment, solutions, and accessories.
Healthcare providers and purchasing organizations have reacted by intensifying supplier qualification processes and by seeking local production partnerships to mitigate exposure to tariff volatility. Regulatory compliance and customs procedures have taken on greater significance, prompting some firms to invest in logistics and trade expertise to navigate classification and duty mitigation strategies. In parallel, innovation pipelines have been reviewed for cost-efficiency in component selection and manufacturing processes, with research and development teams prioritizing designs that permit modular assembly and regional adaptation. As a result, commercial negotiations increasingly emphasize total landed cost, reliability of supply, and contractual protections against future trade disruptions, thereby refocusing strategic planning across the industry.
Segment-driven priorities that clarify product development, clinical focus, and service model adaptations across distinct product, therapeutic, application, and end-user categories
Insights derived from a structured segmentation framework reveal nuanced demand drivers and innovation opportunities across product type, therapeutic area, application, and end user. When viewed by product type, the market encompasses accessories, PD machines, and peritoneal solutions, each provoking distinct development priorities: accessories such as bags for PD solutions, drainage bags, peritoneal dialysis catheter kits, and transfer sets require continuous improvements in aseptic design and user ergonomics to reduce infection risk and simplify home use; PD machines, including automated peritoneal dialysis cyclers and continuous ambulatory peritoneal dialysis devices, generate focus on portability, battery life, connectivity, and user interfaces that enable remote monitoring and clinical oversight; peritoneal solutions, spanning biocompatible solutions, glucose-based solutions, and low-glucose solutions, drive clinical research around membrane preservation, metabolic outcomes, and tolerability.
Shifting to therapeutic area segmentation, acute kidney injury, chronic kidney disease, and congestive heart failure present differing clinical pathways and adoption imperatives, with acute settings prioritizing rapid availability and interchangeable protocols, while chronic care emphasizes long-term tolerability and patient training. Application segmentation underscores the variable etiologies underpinning therapy choice: diabetic nephropathy, glomerulonephritis, lupus nephritis, and polycystic kidney disease each carry distinct comorbidity profiles and treatment adherence challenges that influence product selection and support services. Finally, end-user segmentation across dialysis centers, home healthcare, and hospitals highlights the need for tailored distribution, training, and service models: dialysis centers require volumetric supply and integration with clinical workflows; home healthcare providers need simplified devices, telehealth integration, and caregiver education; hospitals demand rapid case integration and cross-disciplinary protocols. These layered segmentation insights inform prioritization of R&D, commercialization strategies, and service delivery models.
How regional healthcare infrastructures, reimbursement systems, and logistical realities in the Americas, Europe Middle East & Africa, and Asia-Pacific determine commercialization and access approaches
Regional dynamics in peritoneal dialysis reflect differences in healthcare infrastructure, reimbursement paradigms, clinical practice patterns, and supply chain resilience across major geographies. In the Americas, stakeholders contend with a complex payer environment and a mix of large acute care networks and homecare service providers, prompting suppliers to emphasize reimbursement support, training programs, and partnerships that facilitate home therapy initiation. Regulatory pathways and state-level policy variations also influence device registration timelines and pricing strategies, requiring localized market access tactics.
Across Europe, the Middle East & Africa, diverse healthcare systems, public procurement frameworks, and variable infrastructure levels create distinct entry strategies and partnership models. Suppliers often pursue collaborations with regional distributors and clinical champions to demonstrate safety and effectiveness, while also adapting packaging, storage, and service offerings to local logistical realities. Meanwhile, Asia-Pacific presents heterogeneous demand drivers, with some advanced markets accelerating adoption of automation and telehealth-enabled solutions, and others prioritizing cost-efficient disposable accessories and centralized training to scale home-based therapy. In all regions, innovation adoption is moderated by clinician acceptance, patient education, and supply continuity, underscoring the importance of region-specific market intelligence when designing commercial and clinical engagement plans.
Competitive differentiation through integrated device-solution ecosystems, biocompatible chemistry advances, and service-rich commercialization models that drive provider and payer engagement
Competitive positioning within the peritoneal dialysis space is shaped by companies that combine product innovation with service delivery, regulatory expertise, and distribution reach. Leading manufacturers are investing in integrated solutions that couple user-friendly cyclers and accessories with remote monitoring capabilities and training platforms to reduce clinical burden and improve patient retention. Others are differentiating through advances in peritoneal solution chemistry, focusing on formulations that enhance membrane biocompatibility and patient metabolic profiles, thereby addressing long-term therapy durability.
Strategic collaborations and targeted acquisitions are common tactics to broaden portfolios and accelerate entry into adjacent care settings. Firms with robust manufacturing footprints are leveraging scale and quality systems to secure supply contracts with large hospital networks and homecare providers, while emerging entrants often focus on niche innovations-such as simplified transfer sets or infection-resistant catheter materials-to gain clinical traction. Across the competitive landscape, companies that combine clinical evidence generation, post-market support services, and flexible commercial models tend to achieve stronger engagement with payers and providers. Consequently, sustained investment in clinical studies, training infrastructure, and localized regulatory pathways remains central to competitive differentiation.
Practical strategic actions for manufacturers, providers, and payers to align clinical validation, supply chain resilience, service expansion, and digital engagement for scalable growth
Industry leaders should pursue a coordinated set of actions to capitalize on clinical trends and mitigate operational risks while enhancing patient-centric care. First, aligning product development priorities with clinical evidence goals will accelerate adoption; this means designing studies that address membrane preservation, infection reduction, and real-world adherence, and then translating findings into provider-facing value propositions. Second, establishing resilient supply chains is essential: diversifying sourcing, investing in local manufacturing where feasible, and implementing inventory strategies to withstand trade volatility will reduce disruption risk. Third, expanding service offerings-such as remote monitoring, structured training programs, and bundled support for home therapy initiation-will enhance patient outcomes and differentiate commercial propositions.
In addition, companies should foster payer dialogues to articulate total care benefits and to explore reimbursement models that support home-based therapies. Partnerships with dialysis centers, hospitals, and home healthcare organizations can facilitate pilot programs that demonstrate operational feasibility and capture early-adopter feedback. Finally, leveraging digital tools for patient engagement and adherence tracking can generate actionable data for continuous product improvement and for demonstrating value to clinical and financial stakeholders. Together, these actions create synergistic benefits across clinical performance, commercial traction, and supply chain resilience.
A rigorous mixed-methods approach combining clinician and industry interviews, regulatory and clinical literature review, and supply chain analysis to derive balanced sector insights
The research methodology underpinning this analysis integrates multidisciplinary inputs to ensure a robust and balanced view of the peritoneal dialysis landscape. Primary sources included structured interviews with clinical specialists, procurement leaders, and senior executives across device and solution companies, supplemented by consultations with homecare providers and hospital administrators to capture operational perspectives. Secondary research encompassed peer-reviewed clinical literature, regulatory filings, device registries, and policy documents to validate clinical trends and to interpret regulatory and reimbursement contexts.
Qualitative synthesis was applied to reconcile divergent viewpoints and to surface consensus themes, while thematic analysis identified recurring challenges and opportunities across product types, therapeutic areas, and care settings. Supply chain and tariff impact assessments were developed through trade data review and industry stakeholder interviews to capture operational responses and mitigation strategies. Care was taken to cross-validate insights across multiple information streams and to highlight areas where evidence is evolving, ensuring that conclusions reflect current practice and plausible near-term developments rather than speculative projections.
Integrated takeaways that align clinical innovation, adaptive commercialization, and supply chain resilience to advance patient outcomes and organizational competitiveness
In summary, peritoneal dialysis sits at the intersection of clinical innovation, evolving care delivery models, and operational complexity. Advances in automation, biocompatible solutions, and digital monitoring are expanding the clinical viability and appeal of home-based therapy, while tariff-driven supply chain recalibrations and regional healthcare differences require nimble commercial and manufacturing strategies. Segmentation insights point to differentiated needs across products, therapeutic areas, applications, and end users, calling for targeted R&D, tailored training, and adaptive distribution models.
Decision-makers should therefore prioritize investments that strengthen clinical evidence, improve patient support infrastructure, and secure supply chain resilience. By aligning product design with real-world care pathways and by fostering collaborations across providers and payers, organizations can better position themselves to deliver clinical value and to scale services responsibly. As the sector continues to evolve, ongoing monitoring of regulatory shifts, reimbursement policies, and technological breakthroughs will be essential for sustaining competitive advantage and for improving patient outcomes over the long term.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
197 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of remote patient monitoring and telehealth platforms to improve peritoneal dialysis adherence and outcomes
- 5.2. Increasing shift toward home-based automated peritoneal dialysis systems with integrated AI-driven prescription adjustments
- 5.3. Development of biocompatible peritoneal dialysis solutions with neutral pH and reduced glucose degradation products to enhance patient comfort
- 5.4. Growing investment in novel catheter designs and implantable port systems to minimize infection rates and improve patient experience
- 5.5. Advances in wearable peritoneal dialysis devices and continuous flow technologies aiming to reduce treatment burden and enhance quality of life
- 5.6. Expansion of peritoneal dialysis programs in emerging markets driven by cost advantages and localized training initiatives to address chronic kidney disease burden
- 5.7. Integration of data analytics and digital health tools for personalized peritoneal dialysis prescription optimization and risk stratification models
- 5.8. Implementation of patient education and support platforms leveraging gamification to boost adherence and self-care in peritoneal dialysis therapy
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Peritoneal Dialysis Market, by Product Type
- 8.1. Accessories
- 8.1.1. Bags for PD solutions
- 8.1.2. Drainage bags
- 8.1.3. Peritoneal Dialysis Catheter Kit
- 8.1.4. Transfer sets
- 8.2. PD Machines
- 8.2.1. Automated Peritoneal Dialysis Cycler
- 8.2.2. Continuous Ambulatory Peritoneal Dialysis
- 8.3. Peritoneal Solution
- 8.3.1. Biocompatible solutions
- 8.3.2. Glucose-based solutions
- 8.3.3. Low-glucose solutions
- 9. Peritoneal Dialysis Market, by Therapeutic Area
- 9.1. Acute Kidney Injury
- 9.2. Chronic Kidney Disease
- 9.3. Congestive Heart Failure
- 10. Peritoneal Dialysis Market, by Application
- 10.1. Diabetic Nephropathy
- 10.2. Glomerulonephritis
- 10.3. Lupus Nephritis
- 10.4. Polycystic Kidney Disease
- 11. Peritoneal Dialysis Market, by End User
- 11.1. Dialysis Centers
- 11.2. Home Healthcare
- 11.3. Hospitals
- 12. Peritoneal Dialysis Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Peritoneal Dialysis Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Peritoneal Dialysis Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Advin Health Care
- 15.3.2. Angiplast Pvt. Ltd.
- 15.3.3. B. Braun Medical Ltd
- 15.3.4. Baxter International, Inc.
- 15.3.5. Becton, Dickinson and Company
- 15.3.6. Cook Group Incorporated
- 15.3.7. Diaverum AB by M42
- 15.3.8. Fresenius Medical Care AG
- 15.3.9. Huaren Pharmaceutical Co., Ltd.
- 15.3.10. JDmeditech
- 15.3.11. JMS Co., Ltd.
- 15.3.12. Medionics International Inc.
- 15.3.13. Mitra Industries
- 15.3.14. Mozarc Medical
- 15.3.15. Opterion Health AG
- 15.3.16. PFM Medical, Inc.
- 15.3.17. Renax Biomedical Technology Co., Ltd.
- 15.3.18. Renfrew Group International
- 15.3.19. Romsons Prime Private limited
- 15.3.20. Terumo Corporation
- 15.3.21. Toray Industries, Inc.
- 15.3.22. Vivance
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
